AI-Driven Clinical Operations as an Example of URM in Drug Trials: Operational AI, Dynamic Trial Instability, and the Universal Resonance Model

This Perspective examines AI-driven clinical operations as a contemporary example of system dynamics described by the Universal Resonance Model (URM). The analysis takes as its point of departure the article “AI in clinical operations: Can PhaseV’s real-time site optimization reshape IBD trial efficiency?” by Pallavi Madhiraju (2026), together with supporting public material describing PhaseV’s use of causal machine learning, real-time site optimization, IBD Plexus® data, and adaptive operational monitoring in inflammatory bowel disease trials. The text does not introduce new terminology, implementation proposals, optimization procedures, or regulatory recommendations. URM is used strictly as an analytical and interpretive framework grounded in its published corpus. The central claim is that what is framed operationally as AI-based trial optimization can also be read as evidence of URM-relevant dynamics in contemporary drug trials. Viewed through URM, persistent problems in clinical trials — unstable recruitment, site-level variability, protocol deviations, weak predictive value of historical averages, and misalignment between trial planning and real-world disease behavior — are not merely operational inefficiencies. They are manifestations of deeper dynamical instability. AI-driven clinical operations may therefore function as a compensatory layer required because trial architectures remain partly grounded in static assumptions while biological disease systems evolve over time. This Perspective argues that the PhaseV example demonstrates the relevance of URM for understanding bias, instability, timing, and interpretive failure in drug trials. URM is not presented as a replacement for clinical trial methodology, but as an explanatory model that clarifies why adaptive operational technologies have become necessary. Status: Perspective / Preprint — not peer reviewed.